A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Bristol-Myers Squibb
Bristol-Myers Squibb
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tasman Oncology Research
Southport, Queensland, Australia
Recruiting
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Recruiting
- Local Institution - 0007
Los Angeles, California, United States
Active, not recruiting - Local Institution - 0017
Grand Rapids, Michigan, United States
Active, not recruiting - Local Institution - 0004
Hackensack, New Jersey, United States
Active, not recruiting - Local Institution - 0006
Pittsburgh, Pennsylvania, United States
Active, not recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Feb 2025
- Primary completion
- 5 Sept 2026
- Completion
- 9 Dec 2029
- Last update posted
- 2 Jul 2026
- Registered enrollment
- 360
- Registry id
- NCT06730750
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.